Skip to content

The impact of compound Danshen dropping pills on ventricular remodeling and cardiac function after acute anterior wall myocardial infarction: a multicenter, randomized, double-blind, placebo-controlled clinical trial

The impact of compound Danshen dropping pills on ventricular remodeling and cardiac function after acute anterior wall myocardial infarction: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003341
Enrollment
Unknown
Registered
2020-05-25
Start date
2020-05-28
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute anterior wall myocardial infarction

Interventions

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years, gender unlimited; 2. According to the guidelines for diagnosis and treatment of acute ST segment elevation myocardial infarction (2019), patients with acute anterior ST segment elevation myocardial infarction were diagnosed; 3. Patients with primary acute myocardial infarction; 4. Patients who completed PCI reperfusion treatment within 12 hours after the onset of the disease; 5. Patients with Killip grading between I and III; 6. Subjects participated in the study voluntarily and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with previous cardiac insufficiency caused by other diseases (valvular heart disease, congenital heart disease, pericardial disease, arrhythmia, other non cardiac causes); 2. The patients underwent CABG within 12 weeks; 3. Patients undergoing cardiac resynchronization; 4. Patients with left ventricular outflow tract obstruction; 5. Patients with myocarditis; 6. Patients with uncontrolled severe arrhythmia; 7. Patients with aortic aneurysm; 8. Patients with serious liver, kidney, blood system, mental disease or systemic disease; 9. Significant liver and kidney dysfunction (ALT > 2.0 times the upper limit of normal value; creatinine > 1.5 times the upper limit of normal value); 10. Patients with serum potassium > 5.5mmol/l; 11. Uncontrolled hypertension (higher than 180 / 110mmhg); 12. Pregnant or lactating women; 13. Patients allergic to compound Danshen Dropping Pills; 14. Patients participating in clinical studies of other drugs.

Design outcomes

Primary

MeasureTime frame
ultrasonic cardiogram;

Secondary

MeasureTime frame
cardiac arrhythmia;NT-proBNP decline level;Adverse cardiovascular events;

Countries

China

Contacts

Public ContactLiansheng Wang

The First Affiliated Hospital of Nanjing Medical University

drlswang@njmu.edu.cn+86 13390787111

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026